Equities research analysts forecast that Depomed, Inc. (NASDAQ:DEPO) will post earnings per share (EPS) of $0.10 for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Depomed’s earnings, with estimates ranging from $0.09 to $0.11. Depomed posted earnings per share of $0.48 in the same quarter last year, which would suggest a negative year over year growth rate of 79.2%. The company is expected to report its next earnings results on Tuesday, February 20th.

According to Zacks, analysts expect that Depomed will report full year earnings of $0.39 per share for the current fiscal year, with EPS estimates ranging from $0.37 to $0.40. For the next year, analysts anticipate that the business will post earnings of $0.47 per share, with EPS estimates ranging from $0.32 to $0.60. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow Depomed.

Depomed (NASDAQ:DEPO) last announced its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.02. The business had revenue of $95.40 million for the quarter, compared to analyst estimates of $99.11 million. Depomed had a negative net margin of 27.73% and a negative return on equity of 51.07%. The company’s revenue was down 13.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.28 EPS.

A number of research firms have weighed in on DEPO. Piper Jaffray Companies restated a “hold” rating and set a $9.00 price objective on shares of Depomed in a research note on Thursday. BidaskClub raised shares of Depomed from a “sell” rating to a “hold” rating in a report on Wednesday. ValuEngine raised shares of Depomed from a “strong sell” rating to a “sell” rating in a report on Tuesday. Mizuho raised shares of Depomed from a “neutral” rating to a “buy” rating and set a $9.00 price target on the stock in a report on Tuesday. Finally, UBS boosted their target price on shares of Depomed from $6.00 to $7.00 and gave the stock a “neutral” rating in a report on Friday, November 10th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $11.34.

A number of institutional investors have recently added to or reduced their stakes in DEPO. State of Alaska Department of Revenue lifted its holdings in Depomed by 79.5% in the 2nd quarter. State of Alaska Department of Revenue now owns 12,298 shares of the specialty pharmaceutical company’s stock valued at $132,000 after purchasing an additional 5,448 shares in the last quarter. Piedmont Investment Advisors LLC purchased a new position in shares of Depomed during the 2nd quarter worth $145,000. Captrust Financial Advisors purchased a new position in shares of Depomed during the 2nd quarter worth $147,000. Municipal Employees Retirement System of Michigan raised its holdings in shares of Depomed by 4.2% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 14,660 shares of the specialty pharmaceutical company’s stock worth $157,000 after acquiring an additional 590 shares during the period. Finally, BNP Paribas Arbitrage SA raised its holdings in shares of Depomed by 71.0% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 32,251 shares of the specialty pharmaceutical company’s stock worth $187,000 after acquiring an additional 13,388 shares during the period. 90.99% of the stock is currently owned by hedge funds and other institutional investors.

Depomed (NASDAQ:DEPO) traded up $0.25 during trading hours on Thursday, reaching $8.11. 2,494,000 shares of the company’s stock were exchanged, compared to its average volume of 1,651,263. The company has a debt-to-equity ratio of 2.90, a current ratio of 0.83 and a quick ratio of 0.79. Depomed has a 1-year low of $4.31 and a 1-year high of $21.38.

TRADEMARK VIOLATION NOTICE: This story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/12/07/0-10-earnings-per-share-expected-for-depomed-inc-depo-this-quarter.html.

Depomed Company Profile

Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).

Get a free copy of the Zacks research report on Depomed (DEPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Depomed (NASDAQ:DEPO)

Receive News & Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.